Clinical Trial Update: PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating AEVI-001 in children and adolescents with ADHD and mGluR mutations has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• AEVI-001 (null)

Snippet

Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company | Conditions: Attention Deficit Hyperactivity Disorder | Phase 2 | Status: COMPLETED | Results posted: 2019-07-16